SCG’s HBV T-cell therapy shows promise in Phase I trial

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy, SCG101.

The therapy, which targets hepatitis B surface antigen (HBsAg), showed substantial antiviral activity in individuals with advanced HBV-related hepatocellular carcinoma (HBV-HCC).